The Senescent Mesenchymal Stem Cells in Systemic Lupus Erythematosus

ISSN: 2212-389X (Online)
ISSN: 1574-3624 (Print)

Volume 12, 2 Issues, 2017

Download PDF Flyer

Current Signal Transduction Therapy

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

The Senescent Mesenchymal Stem Cells in Systemic Lupus Erythematosus

Current Signal Transduction Therapy, 8(2): 173-177.

Author(s): Guijuan Feng, Wei Tan and Zhifeng Gu.

Affiliation: Department of Rheumatology, Affiliated Hospital of Nantong University, Nantong, China.


Current studies have found that allogenic mesenchymal stem cells (MSCs) transplantation (MSCT) can be used successfully in mouse and human SLE. However, syngeneic bone marrow (BM)-MSCT was ineffective. Recently, studies also revealed that BM-MSCs from SLE patients showed senescent behavior. These findings suggested that the senescence of BM-MSCs from SLE patients may be a contributing factor to disease pathogenesis. So further findings about MSCs senescence of SLE will contribute to lay the groundwork for the development of new therapeutic approaches to treat SLE. In this review, we summarize the characteristics of MSCs, molecular mechanisms and signaling involved in MSCs senescence and the senescent biological behavior of MSCs from SLE and possible mechanisms. Analyzing the mechanisms of controlling MSCs senescence may provide a therapeutic target for SLE.


DNA damage, immunomodulation, Mesenchymal stem cells (MSCs), molecular mechanisms, senescence, Systemic Lupus Erythematosus (SLE).

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 8
Issue Number: 2
First Page: 173
Last Page: 177
Page Count: 5
DOI: 10.2174/15743624113089990003
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science